BMS-754807

BMS-754807 is an orally available, potent, and reversible small molecule inhibitor targeting the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases. Developed by Bristol Myers Squibb, it was investigated primarily as an antineoplastic agent for various solid tumors and hematologic malignancies. The drug acts by binding to IGF-1R and InsR, inhibiting their kinase activity, which leads to reduced tumor cell proliferation and increased apoptosis. Preclinical studies demonstrated its efficacy across a broad range of tumor types including mesenchymal (such as Ewing sarcoma), epithelial (such as breast and lung cancer), and hematopoietic cancers. Clinical development included combination studies with other anticancer agents such as cetuximab. However, clinical trials for breast cancer and solid tumors were discontinued[1][3][5][6].

Other names

1001350-96-4UNII-W9E3353E8JUNII-W-9E3353E8JUNII-W 9E3353E8J